<DOC>
	<DOCNO>NCT00219024</DOCNO>
	<brief_summary>To demonstrate efficacy safety aliskiren give patient essential hypertension , dose 75 mg , 150 mg 300 mg alone , combination hydrochlorothiazide ( HCTZ )</brief_summary>
	<brief_title>Clinical Study Evaluate Efficacy Safety Aliskiren Alone Combination With Hydrochlorothiazide Patients With Essential Hypertension .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Inclusion Criteria Patients essential hypertension Patients eligible able participate study Exclusion Criteria Severe hypertension History evidence secondary form hypertension History hypertensive encephalopathy cerebrovascular accident Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Hypertension , aliskiren , blood pressure , hydrochlorothiazide ( HCTZ ) .</keyword>
</DOC>